FDA grants Cary's Chiesi new designation
With construction of a new headquarters overlooking Symphony Lake currently underway, expanding Cary-based pharmaceutical company Chiesi USA has received a nod from the U.S. Food and Drug Administration for a new stem cell therapy.
Chiesi USA – along with Italian biotech Holostem Terapie Avanzate – have been granted orphan drug designation from the FDA for an investigational therapy for a type of stem cell deficiency. The therapy – called GPLSCD01 – is being developed to treat Limbal Stem…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Grants | Health Management | Italy Health | Stem Cell Therapy | Stem Cells